Title
Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant, Dose-Dense Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer
Phase
Phase 2Lead Sponsor
Emory UniversityStudy Type
InterventionalStatus
Completed Results PostedIndication/Condition
Breast CancerIntervention/Treatment
capecitabine docetaxel ...Study Participants
51The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
The purpose of this study is to identify new chemotherapy treatment regimens with better response rates and to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
Induction chemotherapy offers the possibility of less surgery and determines tumor sensitivity in vivo. Previous trials have demonstrated that complete pathologic response in the breast at surgery corresponds with improved outcome. Additionally, we will correlate specific molecular markers in the breast tumors before and after chemotherapy, with response to treatment. Expression of these molecular markets may be used in the future to predict the likelihood of response to chemotherapy given post-operatively.
Sequential Therapy: Docetaxel will be given at 100 mg/m^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles. Concurrent Therapy: Docetaxel will be given at 50 mg/m^2 IV Day 1.
Sequential Therapy: administration of capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
Docetaxel will be given at 100mg/m^2 intravenous Day 1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).
Docetaxel will be given at 50mg/m^2 Intravenous Day1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
Inclusion Criteria: Histologically or cytologically confirmed breast carcinoma. Early stage breast cancer (stage 1, 2, 3). No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes. 18 years of age or older. Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Exclusion Criteria: Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer. Major surgery within 28 days of study entry. Evidence of central nervous system (CNS) metastases. Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Event Type | Organ System | Event Term | Arm A:Sequential Therapy | Arm B:Concurrent Therapy |
---|
Pathologic complete response (pCR): Absence of invasive breast cancer in the breast. Overall Clinical Response=Complete response(CR-complete disappearance of all measurable malignant disease)+partial response(PR-reduction by at least 30%) Stable disease (SD): No decrease or <25% increase in the sum of the products of the longest perpendicular diameters of all measurable lesions. Progressive disease (PD): A 20% or greater increase in a single lesion, OR reappearance of any lesion which has disappeared, OR clear worsening of any evaluable disease OR appearance of any new lesion/site.
Number of Patients remained alive and relapse free